MX336835B - Metodos y composiciones para el diagnostico y tratamiento de la enfermedad autoinmune secundaria a esclerosis multiple. - Google Patents

Metodos y composiciones para el diagnostico y tratamiento de la enfermedad autoinmune secundaria a esclerosis multiple.

Info

Publication number
MX336835B
MX336835B MX2011003730A MX2011003730A MX336835B MX 336835 B MX336835 B MX 336835B MX 2011003730 A MX2011003730 A MX 2011003730A MX 2011003730 A MX2011003730 A MX 2011003730A MX 336835 B MX336835 B MX 336835B
Authority
MX
Mexico
Prior art keywords
methods
multiple sclerosis
treatment
autoimmune disease
diagnosis
Prior art date
Application number
MX2011003730A
Other languages
English (en)
Other versions
MX2011003730A (es
Inventor
Alasdair J Coles
Joanne L Jones
Alastair Compston
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of MX2011003730A publication Critical patent/MX2011003730A/es
Publication of MX336835B publication Critical patent/MX336835B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invención se refiere a métodos para diagnosticar a pacientes con esclerosis múltiple (MS), incluyendo métodos para identificar a pacientes con esclerosis múltiple que están en riesgo incrementado de desarrollar una enfermedad autoinmune secundaria después del agotamiento de linfocitos ocasionada, por ejemplo, por el tratamiento con un anticuerpo anti-CD52. También se abarcan métodos para seleccionar regímenes de tratamiento para pacientes con MS, y reactivos útiles en los métodos mencionados anteriormente.
MX2011003730A 2008-10-08 2009-10-08 Metodos y composiciones para el diagnostico y tratamiento de la enfermedad autoinmune secundaria a esclerosis multiple. MX336835B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19565808P 2008-10-08 2008-10-08
US19718708P 2008-10-24 2008-10-24
US19863108P 2008-11-07 2008-11-07
PCT/IB2009/007327 WO2010041149A2 (en) 2008-10-08 2009-10-08 Methods and compositions for diagnosis and treatment

Publications (2)

Publication Number Publication Date
MX2011003730A MX2011003730A (es) 2011-07-28
MX336835B true MX336835B (es) 2016-02-03

Family

ID=42061141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011003730A MX336835B (es) 2008-10-08 2009-10-08 Metodos y composiciones para el diagnostico y tratamiento de la enfermedad autoinmune secundaria a esclerosis multiple.

Country Status (22)

Country Link
US (4) US20110229470A1 (es)
EP (2) EP3241910B1 (es)
JP (2) JP5856481B2 (es)
KR (2) KR101825457B1 (es)
CN (1) CN102245783B (es)
AU (1) AU2009302117B2 (es)
BR (1) BRPI0920546B1 (es)
CA (1) CA2740077A1 (es)
CY (1) CY1119513T1 (es)
DK (1) DK2344677T3 (es)
ES (2) ES2784830T3 (es)
HK (1) HK1246364A1 (es)
HR (1) HRP20171023T1 (es)
HU (1) HUE035208T2 (es)
IL (1) IL212069A (es)
LT (1) LT2344677T (es)
MX (1) MX336835B (es)
PL (2) PL3241910T3 (es)
PT (2) PT3241910T (es)
RU (1) RU2563521C2 (es)
SI (1) SI2344677T1 (es)
WO (1) WO2010041149A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835819A1 (en) 2011-05-16 2012-11-22 Genzyme Corporation Induction of immune tolerance using methotrexate
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
MA37681B2 (fr) * 2012-05-25 2020-07-29 Cellectis Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
CN102786595B (zh) * 2012-08-03 2014-04-23 无锡傲锐东源生物科技有限公司 抗cd5蛋白单克隆抗体及其用途
KR20230164204A (ko) 2016-03-10 2023-12-01 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
EP3487875A4 (en) * 2016-07-19 2020-02-12 Arete Discoveries, Inc. BIOMARKERS FOR THE DETECTION AND TREATMENT OF DISORDERS ASSOCIATED WITH THE ACTIVITY OF MASTOCYTES
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US11672092B2 (en) * 2019-11-06 2023-06-06 Steiner Enterprises Modular electrical distribution system for vehicles
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
EP4337958A1 (en) * 2021-05-13 2024-03-20 Genzyme Corporation Novel predictive biomarkers for secondary autoimmunity after lymphocyte depleting therapy
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6351720B1 (en) 1997-10-24 2002-02-26 Mitsubishi Heavy Industries, Ltd. Trolley camera position detecting apparatus
US6045501A (en) * 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
JP2005501545A (ja) 2001-09-04 2005-01-20 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド カスパーゼ結合タンパク質、その調製物および使用
AU2002336676A1 (en) * 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
WO2003050257A2 (en) 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
PT1531850E (pt) 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
CN1849131A (zh) * 2003-03-21 2006-10-18 Wyeth公司 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病
EP1670501A2 (en) * 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
EP1773394A2 (en) 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Antagonizing interleukin-21 receptor activity
EP2567973B1 (en) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists

Also Published As

Publication number Publication date
PL3241910T3 (pl) 2020-10-19
IL212069A (en) 2016-04-21
ES2632213T3 (es) 2017-09-11
EP2344677A2 (en) 2011-07-20
EP3241910B1 (en) 2020-01-08
JP5856481B2 (ja) 2016-02-09
MX2011003730A (es) 2011-07-28
HK1246364A1 (zh) 2018-09-07
CN102245783A (zh) 2011-11-16
KR20110094276A (ko) 2011-08-23
WO2010041149A3 (en) 2010-09-30
SI2344677T1 (sl) 2017-10-30
JP2014195462A (ja) 2014-10-16
US20200191799A1 (en) 2020-06-18
RU2011118477A (ru) 2012-11-20
BRPI0920546A2 (pt) 2020-06-02
RU2563521C2 (ru) 2015-09-20
JP2012504954A (ja) 2012-03-01
US11243211B2 (en) 2022-02-08
PL2344677T3 (pl) 2017-11-30
US10598670B2 (en) 2020-03-24
HUE035208T2 (hu) 2018-05-02
DK2344677T3 (en) 2017-07-24
US20160356788A1 (en) 2016-12-08
HRP20171023T1 (hr) 2017-10-06
US20110229470A1 (en) 2011-09-22
CA2740077A1 (en) 2010-04-15
LT2344677T (lt) 2017-09-25
EP2344677B1 (en) 2017-04-05
KR101825457B1 (ko) 2018-02-05
PT3241910T (pt) 2020-04-07
AU2009302117B2 (en) 2016-07-28
EP3241910A1 (en) 2017-11-08
CY1119513T1 (el) 2018-03-07
KR20160140984A (ko) 2016-12-07
AU2009302117A1 (en) 2010-04-15
ES2784830T3 (es) 2020-10-01
US20220349899A1 (en) 2022-11-03
IL212069A0 (en) 2011-06-30
WO2010041149A2 (en) 2010-04-15
PT2344677T (pt) 2017-07-13
BRPI0920546B1 (pt) 2021-08-10
CN102245783B (zh) 2015-12-16
KR101682730B1 (ko) 2016-12-05

Similar Documents

Publication Publication Date Title
MX336835B (es) Metodos y composiciones para el diagnostico y tratamiento de la enfermedad autoinmune secundaria a esclerosis multiple.
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MA34641B1 (fr) Anticorps anti-il-23
AR048888A1 (es) Prevencion de una enfermedad autoinmune
HK1145087A1 (en) Diagnostic agent
EA201100231A1 (ru) Диагностический анализ на основе антител
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
MA35180B1 (fr) Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b
MA29528B1 (fr) Agents de fixation
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
EA201001874A1 (ru) Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
TW200639404A (en) Method of assessing the effectiveness of a treatment regimen
WO2009055001A3 (en) Methods of treating aging and methods of screening candidate agents therefor
BRPI0815460A2 (pt) kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos
NZ729773A (en) Biomarkers for disease progression in melanoma
WO2011044125A8 (en) A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
WO2005121366A8 (ja) 遺伝子マーカー及びその利用
MX343873B (es) Ensayo de diagnostico de anticuerpo.

Legal Events

Date Code Title Description
FG Grant or registration